AstraZeneca obtains rights to Actavis' Branded Respiratory Portfolio in the U.S. and Canada
Under a final agreement between AstraZeneca and Actavis, AstraZeneca will procure the rights to Actavis’ proprietary respiratory business in the United States and Canada, the two companies announced on Feb. 5. Read More »